Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 11:53AM ET
27.24
Dollar change
+0.22
Percentage change
0.80
%
IndexRUT P/E- EPS (ttm)-5.42 Insider Own2.30% Shs Outstand96.11M Perf Week-1.50%
Market Cap2.62B Forward P/E- EPS next Y-5.64 Insider Trans-2.37% Shs Float93.89M Perf Month-16.97%
Income-481.19M PEG- EPS next Q-1.38 Inst Own85.60% Short Float14.38% Perf Quarter-14.19%
Sales36.27M P/S72.17 EPS this Y-2.56% Inst Trans-0.30% Short Ratio8.55 Perf Half Y-15.13%
Book/sh11.29 P/B2.41 EPS next Y-1.39% ROA-34.11% Short Interest13.50M Perf Year-24.39%
Cash/sh9.49 P/C2.87 EPS next 5Y30.00% ROE-42.10% 52W Range22.67 - 47.48 Perf YTD-10.68%
Dividend Est.- P/FCF- EPS past 5Y-22.30% ROI-41.96% 52W High-42.64% Beta1.77
Dividend TTM- Quick Ratio8.67 Sales past 5Y12.09% Gross Margin75.26% 52W Low20.16% ATR (14)1.46
Dividend Ex-Date- Current Ratio8.67 EPS Y/Y TTM12.31% Oper. Margin-1420.51% RSI (14)45.70 Volatility4.12% 5.55%
Employees526 Debt/Eq0.11 Sales Y/Y TTM-30.40% Profit Margin-1326.51% Recom1.54 Target Price69.96
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q-4.64% Payout- Rel Volume0.33 Prev Close27.02
Sales Surprise-115.04% EPS Surprise-1.49% Sales Q/Q-114.12% EarningsFeb 22 BMO Avg Volume1.58M Price27.24
SMA20-5.54% SMA50-1.15% SMA200-16.48% Trades Volume205,870 Change0.80%
Date Action Analyst Rating Change Price Target Change
Feb-23-24Downgrade Goldman Buy → Neutral $136 → $32
Feb-15-24Initiated Wolfe Research Peer Perform
Apr-13-23Initiated Canaccord Genuity Buy $66
Mar-21-23Initiated Bernstein Outperform $54
Mar-14-23Upgrade BMO Capital Markets Market Perform → Outperform $54 → $57
Feb-01-23Initiated Cantor Fitzgerald Overweight $67
Jan-24-23Upgrade Citigroup Sell → Neutral $48 → $39
Jan-19-23Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-11-22Initiated Morgan Stanley Overweight $84
Sep-21-22Initiated JP Morgan Overweight $85
Today 05:55AM
Mar-21-24 05:29PM
04:19PM
Mar-19-24 01:06PM
Mar-18-24 07:30AM
09:45AM Loading…
Mar-09-24 09:45AM
Mar-06-24 10:35AM
Mar-01-24 01:43PM
Feb-29-24 05:50AM
Feb-28-24 09:30AM
Feb-27-24 11:55AM
09:35AM
Feb-23-24 12:22PM
11:12AM
09:55AM
10:53PM Loading…
Feb-22-24 10:53PM
08:12AM
07:30AM
Feb-20-24 05:02AM
Feb-17-24 01:59AM
Feb-15-24 10:00AM
07:30AM
06:20AM
Feb-14-24 07:30AM
Feb-13-24 06:05AM
Feb-10-24 05:09PM
Feb-08-24 01:15PM
Feb-07-24 11:50AM
Feb-05-24 05:25AM
Jan-31-24 05:00PM
12:28PM Loading…
12:28PM
Jan-30-24 05:10AM
Jan-29-24 09:35AM
Jan-27-24 01:25PM
08:55AM
Jan-24-24 07:00AM
Jan-22-24 05:41PM
Jan-21-24 08:00AM
Jan-18-24 11:50AM
Jan-13-24 06:05AM
Jan-12-24 08:44AM
Jan-08-24 07:45AM
05:52AM
Jan-05-24 10:04AM
Jan-04-24 04:01PM
12:47PM
Dec-31-23 08:45AM
Dec-27-23 06:41PM
Dec-16-23 05:00AM
Dec-13-23 05:20AM
Dec-12-23 06:00AM
Dec-10-23 11:57AM
Nov-28-23 05:30AM
Nov-24-23 07:00AM
Nov-15-23 11:07AM
Nov-14-23 07:30AM
Nov-10-23 05:38PM
06:30AM
Nov-09-23 04:06PM
03:37PM
08:29AM
07:30AM
Nov-06-23 08:02AM
Nov-02-23 07:00AM
06:45AM
Oct-30-23 03:46PM
10:00AM
Oct-28-23 07:30AM
Oct-26-23 10:02AM
07:30AM
Oct-23-23 09:40AM
08:45AM
Oct-21-23 05:00AM
Oct-19-23 11:46AM
Oct-18-23 04:10PM
07:00AM
Oct-16-23 12:39PM
10:43AM
Oct-14-23 12:20PM
Oct-13-23 08:38AM
Oct-12-23 08:57AM
Oct-10-23 02:00PM
10:07AM
Oct-06-23 04:59AM
Oct-05-23 09:15AM
Oct-04-23 09:27AM
Oct-03-23 10:07AM
07:58AM
07:08AM
07:00AM
Sep-23-23 09:45AM
Sep-10-23 08:15AM
Sep-09-23 03:59PM
Sep-06-23 02:00PM
Sep-05-23 09:52AM
Sep-01-23 10:00AM
Aug-31-23 05:42AM
Aug-30-23 09:37AM
Aug-24-23 10:29AM
Aug-23-23 11:15AM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BASTA JAMESEVP, General CounselMar 04 '24Sale32.992,29775,77881,571Mar 05 04:10 PM
Clark ElianaEVP, Chief Technical OfficerMar 04 '24Sale32.9960519,95971,470Mar 05 04:10 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerJan 08 '24Sale28.872,27565,68243,927Jan 10 04:15 PM
LEONARD JOHN MPresident and CEOJan 03 '24Sale29.4619,223566,310846,486Jan 05 04:51 PM
Lebwohl DavidEVP, Chief Medical OfficerJan 03 '24Sale29.465,843172,13554,372Jan 05 04:50 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerJan 03 '24Sale29.465,532162,97346,202Jan 05 04:50 PM
Goddard GlennEVP, Chief Financial OfficerJan 03 '24Sale29.465,365158,05340,585Jan 05 04:49 PM
Clark ElianaEVP, Chief Technical OfficerJan 03 '24Sale29.504,608135,95440,845Jan 05 04:44 PM
Hicks DerekEVP, Chief Business OfficerJan 03 '24Sale29.463,877114,21636,987Jan 05 04:46 PM
BASTA JAMESEVP, General CounselJan 03 '24Sale29.463,805112,09551,474Jan 05 04:45 PM
Bhanji MunaDirectorOct 31 '23Sale23.902656,33411,996Nov 02 04:42 PM
Bhanji MunaDirectorJul 31 '23Sale42.3326511,21712,261Aug 02 05:19 PM
Bhanji MunaDirectorJul 06 '23Sale39.301,86773,37312,526Jul 10 05:21 PM
Clark ElianaEVP, Chief Technical OfficerJul 03 '23Sale40.5136014,58445,146Jul 06 03:34 PM
Clark ElianaEVP, Chief Technical OfficerJun 20 '23Option Exercise12.275,00061,35050,146Jun 22 05:52 PM
Clark ElianaEVP, Chief Technical OfficerJun 20 '23Sale45.005,000225,00045,146Jun 22 05:52 PM
Last Close
Mar 28 11:53AM ET
251.90
Dollar change
-0.67
Percentage change
-0.27
%
IQV IQVIA Holdings Inc daily Stock Chart
IndexS&P 500 P/E34.50 EPS (ttm)7.30 Insider Own1.14% Shs Outstand181.50M Perf Week-1.04%
Market Cap45.85B Forward P/E20.06 EPS next Y12.56 Insider Trans-3.80% Shs Float179.94M Perf Month0.64%
Income1.36B PEG2.71 EPS next Q2.48 Inst Own91.36% Short Float1.78% Perf Quarter8.62%
Sales14.96B P/S3.06 EPS this Y8.94% Inst Trans0.41% Short Ratio3.15 Perf Half Y24.57%
Book/sh33.67 P/B7.48 EPS next Y12.98% ROA5.22% Short Interest3.20M Perf Year32.67%
Cash/sh8.22 P/C30.65 EPS next 5Y12.71% ROE22.87% 52W Range167.42 - 261.73 Perf YTD8.87%
Dividend Est.- P/FCF30.57 EPS past 5Y42.42% ROI6.96% 52W High-3.76% Beta1.51
Dividend TTM- Quick Ratio0.86 Sales past 5Y7.76% Gross Margin27.35% 52W Low50.46% ATR (14)5.00
Dividend Ex-Date- Current Ratio0.86 EPS Y/Y TTM27.39% Oper. Margin13.63% RSI (14)55.93 Volatility1.65% 1.85%
Employees87000 Debt/Eq2.33 Sales Y/Y TTM3.75% Profit Margin9.08% Recom1.62 Target Price272.91
Option/ShortYes / Yes LT Debt/Eq2.19 EPS Q/Q111.43% Payout0.00% Rel Volume0.38 Prev Close252.57
Sales Surprise1.91% EPS Surprise0.66% Sales Q/Q3.20% EarningsFeb 14 BMO Avg Volume1.01M Price251.90
SMA20-0.58% SMA506.80% SMA20015.48% Trades Volume153,561 Change-0.27%
Date Action Analyst Rating Change Price Target Change
Feb-26-24Initiated Leerink Partners Outperform $290
Feb-15-24Downgrade Guggenheim Buy → Neutral
Feb-13-24Initiated BTIG Research Buy $285
Nov-02-23Downgrade Robert W. Baird Outperform → Neutral $248 → $202
Sep-06-23Initiated HSBC Securities Buy $260
Mar-17-23Initiated Truist Buy $265
Dec-06-22Initiated Cowen Outperform $251
Nov-17-22Downgrade Citigroup Buy → Neutral $275 → $245
Aug-25-22Initiated Credit Suisse Outperform $300
Jul-15-22Initiated SVB Leerink Outperform $256
Mar-20-24 07:44PM
Mar-15-24 01:38PM
11:30AM
Mar-13-24 12:07PM
Mar-06-24 04:15PM
08:00AM Loading…
Feb-27-24 08:00AM
Feb-26-24 08:00AM
Feb-23-24 09:00AM
Feb-21-24 04:15PM
Feb-16-24 12:02AM
Feb-15-24 05:34PM
10:39AM
01:30AM
Feb-14-24 06:29PM
01:00PM
09:30AM Loading…
09:30AM
08:10AM
07:36AM
07:33AM
07:16AM
07:00AM
Feb-09-24 09:26AM
09:15AM
Feb-06-24 09:00AM
Jan-24-24 04:15PM
Jan-18-24 12:49PM
Jan-17-24 06:00AM
Jan-10-24 06:29PM
06:16PM
Jan-03-24 10:31AM
08:15AM Loading…
Jan-02-24 08:15AM
Dec-29-23 09:31PM
09:18PM
Dec-28-23 06:30PM
Dec-07-23 11:53AM
Dec-01-23 11:31AM
Nov-29-23 08:30AM
Nov-21-23 04:15PM
Nov-20-23 12:34PM
Nov-17-23 09:23AM
Nov-15-23 09:11AM
Nov-14-23 09:07AM
Nov-06-23 08:00AM
Nov-04-23 01:18PM
Nov-02-23 03:52PM
11:25AM
09:30AM
01:15AM
Nov-01-23 11:43PM
11:36AM
09:36AM
08:34AM
08:25AM
08:16AM
08:04AM
07:30AM
07:00AM
Oct-30-23 04:21PM
10:00AM
Oct-26-23 12:10PM
10:45AM
Oct-25-23 10:02AM
Oct-23-23 08:00AM
Oct-20-23 07:39AM
04:23AM
Oct-19-23 06:54AM
Oct-17-23 09:07AM
Oct-11-23 07:30AM
Oct-09-23 04:15PM
07:19AM
Oct-05-23 08:13AM
08:00AM
Oct-03-23 08:00AM
Sep-29-23 03:57PM
03:15PM
Sep-25-23 08:01PM
Sep-14-23 12:44PM
Sep-12-23 08:30AM
Sep-08-23 02:13PM
11:36AM
11:31AM
Sep-05-23 08:30AM
Sep-01-23 08:30AM
Aug-31-23 11:31AM
Aug-30-23 08:54AM
Aug-25-23 02:15PM
Aug-18-23 07:39AM
Aug-16-23 08:42PM
Aug-14-23 04:33PM
Aug-12-23 10:00AM
Aug-11-23 12:05PM
Aug-06-23 08:00AM
Aug-02-23 02:56PM
01:52PM
12:46AM
Aug-01-23 12:59PM
10:30AM
09:22AM
08:15AM
07:11AM
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOUSBIB ARISee RemarksMar 01 '24Option Exercise65.1642,8472,791,911828,430Mar 04 05:28 PM
BOUSBIB ARISee RemarksMar 01 '24Sale250.5331,6787,936,193796,752Mar 04 05:28 PM
STAUB W RICHARDSee RemarksFeb 29 '24Sale247.8014,1003,494,03415,945Mar 04 05:27 PM
Knightly Kevin CSee RemarksFeb 28 '24Option Exercise87.4013,2061,154,21113,858Mar 01 05:07 PM
Knightly Kevin CSee RemarksFeb 28 '24Sale250.178,6072,153,1765,251Mar 01 05:07 PM
Knightly Kevin CSee RemarksFeb 16 '24Option Exercise78.2112,149950,17318,061Feb 21 05:07 PM
Knightly Kevin CSee RemarksFeb 16 '24Sale241.1013,4683,247,165652Feb 21 05:07 PM
Sherbet EricSee RemarksFeb 16 '24Sale241.501,000241,50020,836Feb 21 05:08 PM
Knightly Kevin CSee RemarksDec 01 '23Option Exercise62.2618,4911,151,18520,464Dec 05 05:01 PM
Knightly Kevin CSee RemarksDec 01 '23Sale214.0313,1172,807,4727,347Dec 05 05:01 PM
Panagos ConstantinosSee RemarksSep 19 '23Option Exercise149.4526,1863,913,56340,436Sep 21 05:01 PM
Panagos ConstantinosSee RemarksSep 19 '23Sale208.6727,3175,700,34014,250Sep 21 05:01 PM
Knightly Kevin CSee RemarksJun 05 '23Sale201.895,8201,175,0000Jun 07 05:31 PM
Knightly Kevin CSee RemarksMay 26 '23Sale198.6611990May 31 09:29 PM